Vanguard Group Inc. Acquires 666,357 Shares of Omeros Corporation $OMER

Vanguard Group Inc. increased its position in shares of Omeros Corporation (NASDAQ:OMER) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,013,315 shares of the biopharmaceutical company’s stock after purchasing an additional 666,357 shares during the period. Vanguard Group Inc. owned 5.66% of Omeros worth $68,929,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Two Sigma Investments LP raised its position in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after purchasing an additional 263,095 shares during the period. Marshall Wace LLP raised its position in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 97,224 shares during the period. JPMorgan Chase & Co. raised its position in shares of Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. Millennium Management LLC raised its position in shares of Omeros by 49.1% during the 3rd quarter. Millennium Management LLC now owns 401,814 shares of the biopharmaceutical company’s stock valued at $1,647,000 after purchasing an additional 132,393 shares during the period. Finally, Squarepoint Ops LLC raised its position in shares of Omeros by 75.8% during the 3rd quarter. Squarepoint Ops LLC now owns 155,496 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 67,021 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on OMER shares. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Omeros in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Performance

OMER opened at $13.28 on Friday. The stock has a market capitalization of $958.42 million, a price-to-earnings ratio of 18.97 and a beta of 2.66. The company has a fifty day moving average of $12.25 and a 200 day moving average of $11.39. Omeros Corporation has a fifty-two week low of $2.95 and a fifty-two week high of $17.65.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $4.19 million. On average, equities research analysts forecast that Omeros Corporation will post -1.54 earnings per share for the current year.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.